僧帽弁疾患治療の世界市場

僧帽弁疾患治療の世界市場は2030年までに6億8,900万米ドルに達する見込み

2024年に6億2,490万米ドルと推定される僧帽弁疾患治療の世界市場は、分析期間2024-2030年にCAGR 1.6%で成長し、2030年には6億8,900万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるβ遮断薬は、CAGR 1.4%を記録し、分析期間終了時には3億790万米ドルに達すると予測されます。利尿薬セグメントの成長率は、分析期間中CAGR 1.3％と推定されます。

米国市場は1億7,030万米ドルと推定、中国はCAGR 3.1％で成長予測

米国の僧帽弁疾患治療市場は、2024年に1億7,030万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億2,600万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7%と1.4%と予測されています。欧州では、ドイツがCAGR約0.9%で成長すると予測されています。

世界の僧帽弁疾患治療市場- 主要動向と促進要因まとめ

僧帽弁疾患が心血管治療薬の臨床的・商業的注目を集める理由とは？

僧帽弁閉鎖不全症（MR）や僧帽弁狭窄症（MS）などの疾患を含む僧帽弁疾患は、特に高齢化社会における世界の心血管疾患の罹患率および死亡率の主な原因となっています。左心房と左心室の間の血流を調節する僧帽弁の機能不全によって特徴づけられるこの疾患は、治療されなければ逆流、圧負荷、肺高血圧、心房細動、そして最終的には心不全に至る。その進行性の性質と複雑な病態生理を考えると、不可逆的な心臓のリモデリングと死亡を防ぐためには、早期診断と適切な介入が不可欠です。

人口動態の高齢化、リウマチ性心疾患の流行、早期心臓インターベンションによる生存率の向上などにより、僧帽弁疾患の負担は先進国でも開発途上国でも急増しています。歴史的に診断や治療が不十分であった僧帽弁疾患は、心エコー検査によるスクリーニングの増加、循環器専門医の意識の向上、低侵襲治療における技術的進歩により、現在再び注目を集めています。このため、外科的修復、経カテーテル弁治療、薬理学的管理、デバイスを用いた介入など、治療市場が拡大しています。

経カテーテル的介入と外科的進歩はどのように治療の展望を変えているのか？

僧帽弁疾患の治療パラダイムは、従来の開心術から、より侵襲の少ない経カテーテル的アプローチへと移行しつつあります。外科的な僧帽弁形成術や弁置換術は、若く健康な患者にとっては依然としてゴールドスタンダードであるが、高齢者やリスクの高い患者の多くはそのような手術の理想的な候補者ではないです。このような状況において、経カテーテル僧帽弁修復（TMVR）システム-MitraClip（Abbott社製）やPASCALシステム（Edwards Lifesciences社製）など-は、機能的MRや変性MRに対する有効性が証明された経皮的代替手段を提供することにより、管理に革命をもたらしました。

これらのシステムは、大腿動脈からカテーテルを挿入することにより、リーフレットのコアプタシオンや環状形成術を可能にし、入院時間、手技リスク、回復期間を大幅に短縮しています。同時に、主にACE阻害薬、β遮断薬、利尿薬からなる薬物療法は、症状の緩和と心不全の合併症の管理のために依然として重要です。ロボット支援弁修復術、低侵襲胸腔鏡手術、高度な画像誘導による術中計画などの外科的技術革新は、手技の精度と患者の転帰をさらに向上させています。僧帽弁形成術と左心房付属器閉鎖術、肺静脈隔離術、弁膜下インターベンションを組み合わせた次世代デバイスの臨床試験が進行中です。

僧帽弁治療の世界の普及を牽引している患者層、治療環境、市場とは？

僧帽弁疾患治療の中心的な患者層は65歳以上で、多くの場合、高血圧、心房細動、糖尿病などの複数の併存疾患を抱えています。外来循環器科クリニックやプライマリ・ケアにおける心血管スクリーニング率の上昇により、無症候性または潜在性MRの発見が増加しています。インターベンショナル・カーディオロジスト、心臓外科医、画像診断の専門家で構成される病院を拠点とする心臓チームは、心エコー検査によるグレード付けとリスク層別化ツールに基づく治療方針の決定において重要な役割を果たしています。

北米と西欧は、有利な償還制度、整備された心臓インフラ、早期の規制承認により、TMVR技術の採用でリードしています。アジア太平洋地域、特に日本と中国は、高齢者人口の増加、専門的心臓治療へのアクセスの改善、医療機器イノベーションへの投資によって急速な成長を遂げています。ラテンアメリカ、東欧、中東は新興市場であり、外科的治療が依然として主流であるが、カテーテルを用いた治療への関心が高まりつつあり、治療の嗜好が変わり始めています。

僧帽弁疾患治療市場の長期的な成長とイノベーションの原動力は？

僧帽弁疾患治療市場の成長は、人口動態の動向、機器の革新、臨床ガイドラインの更新、アウトカムベースのヘルスケアモデルの融合によって促進されています。心血管治療がますます個別化されるにつれ、侵襲の少ない、画像誘導された、患者に合わせた弁修復ソリューションへの需要が加速しています。マルチモーダル画像診断、リスク予測のための機械学習、治療アルゴリズムへの実世界データの統合が、診断と手技計画の精度を高めています。

TMVR手技に対する支払者の支援、TAVR（経カテーテル的大動脈弁置換術）インフラの僧帽弁適用への拡大、および専門分野を超えた連携が、より広範な採用の可能性を引き出しています。さらに、索状修復システム、環状形成リング、高分子人工弁などのパイプライン技術は、治療ツールキットを多様化しています。血行動態の安定化と機械的矯正を組み合わせた、医薬品とデバイスのハイブリッド・アプローチは、心不全に関連したMR管理において関心を集めています。

構造的心疾患の治療が外科手術の領域を超えて進化するにつれて、僧帽弁治療薬は心臓技術革新の最前線にあり続け、手技の有効性、患者の安全性、ヘルスケア資源の最適化をバランスよく実現する成果をもたらすと思われます。

セグメント

薬剤クラス（β遮断薬、利尿薬、抗凝固薬、その他薬剤クラス別）;年齢層（55歳未満、55歳以上）;販売チャネル（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）

調査対象企業の例（注目43社）

• 4C Medical Technologies
• Abbott Laboratories
• Affluent Medical
• Anteris Technologies
• Artivion, Inc.
• Bayer AG
• Boston Scientific Corporation
• Cadrenal Therapeutics, Inc.
• Colibri Heart Valve LLC
• Corcym UK Limited
• CryoLife, Inc.
• Edwards Lifesciences Corporation
• HighLife Medical
• Labcor Laboratorios Ltda
• Lepu Medical Technology Co., Ltd.
• LivaNova PLC
• Medtronic plc
• Micro Interventional Devices, Inc.
• Novartis AG
• Zydus Lifesciences Limited

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Mitral Valve Disease Therapeutics Market to Reach US$689.0 Million by 2030

The global market for Mitral Valve Disease Therapeutics estimated at US$624.9 Million in the year 2024, is expected to reach US$689.0 Million by 2030, growing at a CAGR of 1.6% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$307.9 Million by the end of the analysis period. Growth in the Diuretics segment is estimated at 1.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.3 Million While China is Forecast to Grow at 3.1% CAGR

The Mitral Valve Disease Therapeutics market in the U.S. is estimated at US$170.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.0 Million by the year 2030 trailing a CAGR of 3.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Mitral Valve Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Is Mitral Valve Disease Receiving Greater Clinical and Commercial Attention in Cardiovascular Therapeutics?

Mitral valve disease, encompassing conditions such as mitral regurgitation (MR) and mitral stenosis (MS), is a major contributor to global cardiovascular morbidity and mortality, particularly among aging populations. Characterized by malfunctioning of the mitral valve-which regulates blood flow between the left atrium and left ventricle-the disease leads to backflow, pressure overload, pulmonary hypertension, atrial fibrillation, and eventually heart failure if untreated. Given its progressive nature and complex pathophysiology, early diagnosis and tailored intervention are vital to prevent irreversible cardiac remodeling and death.

The burden of mitral valve disease is rising sharply in both developed and developing regions due to aging demographics, rheumatic heart disease prevalence, and improved survival from earlier cardiac interventions. Historically underdiagnosed and undertreated, mitral valve conditions are now receiving renewed attention owing to increased screening via echocardiography, greater awareness among cardiologists, and technological breakthroughs in minimally invasive therapies. This has led to an expanding therapeutic market that spans surgical repair, transcatheter valve therapy, pharmacological management, and device-based interventions.

How Are Transcatheter Interventions and Surgical Advances Transforming the Treatment Landscape?

The treatment paradigm for mitral valve disease is shifting from traditional open-heart surgery toward less invasive transcatheter approaches. Surgical mitral valve repair and replacement remain the gold standard in younger and healthier patients; however, many elderly or high-risk patients are not ideal candidates for such procedures. In this context, transcatheter mitral valve repair (TMVR) systems-such as the MitraClip (Abbott) and the PASCAL system (Edwards Lifesciences)-have revolutionized management by offering percutaneous alternatives with proven efficacy in functional and degenerative MR.

These systems enable leaflet coaptation or annuloplasty through catheter-based insertion via femoral access, significantly reducing hospitalization time, procedural risk, and recovery duration. Concurrently, pharmacotherapy-primarily comprising ACE inhibitors, beta-blockers, and diuretics-remains critical for symptom relief and management of heart failure comorbidities. Surgical innovations such as robotic-assisted valve repair, minimally invasive thoracotomy, and advanced imaging-guided intraoperative planning are further enhancing procedural precision and patient outcomes. Clinical trials are ongoing for next-generation devices that combine mitral repair with left atrial appendage closure, pulmonary vein isolation, or subvalvular interventions.

Which Patient Populations, Care Settings, and Markets Are Driving Global Adoption of Mitral Valve Therapies?

The core patient demographic for mitral valve disease therapies comprises individuals aged 65 and above, often presenting with multiple comorbidities such as hypertension, atrial fibrillation, and diabetes. Rising cardiovascular screening rates in outpatient cardiology clinics and primary care settings are increasing detection of asymptomatic or subclinical MR. Hospital-based heart teams, consisting of interventional cardiologists, cardiac surgeons, and imaging specialists, play a key role in therapeutic decision-making based on echocardiographic grading and risk stratification tools.

North America and Western Europe are leading in adoption of TMVR technologies due to favorable reimbursement systems, well-developed cardiac infrastructure, and early regulatory approvals. The Asia-Pacific region, particularly Japan and China, is witnessing rapid growth driven by increasing elderly populations, improved access to specialty cardiac care, and investment in medical device innovation. Latin America, Eastern Europe, and the Middle East are emerging markets where surgical options remain dominant, but growing interest in catheter-based therapies is beginning to reshape treatment preferences.

What Is Driving Long-Term Growth and Innovation in the Mitral Valve Disease Therapeutics Market?

The growth in the mitral valve disease therapeutics market is being fueled by the convergence of demographic trends, device innovation, clinical guideline updates, and outcome-based healthcare models. As cardiovascular care becomes increasingly personalized, the demand for less invasive, image-guided, and patient-tailored valve repair solutions is accelerating. Multi-modal imaging, machine learning for risk prediction, and integration of real-world data into therapeutic algorithms are enhancing diagnosis and procedural planning accuracy.

Payer support for TMVR procedures, expansion of TAVR (transcatheter aortic valve replacement) infrastructure to mitral applications, and cross-specialty collaboration are unlocking broader adoption. Additionally, pipeline technologies such as chordal repair systems, annuloplasty rings, and polymeric valve prostheses are diversifying the therapeutic toolkit. Pharma-device hybrid approaches-combining hemodynamic stabilization with mechanical correction-are gaining interest in heart failure-associated MR management.

As structural heart disease management evolves beyond surgical dominion, mitral valve therapeutics will remain at the forefront of cardiac innovation-delivering outcomes that balance procedural efficacy, patient safety, and healthcare resource optimization.

SCOPE OF STUDY:

The report analyzes the Mitral Valve Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Beta Blockers, Diuretics, Anticoagulants, Other Drug Classes); Age Group (Below 55 Years, Above 55 Years); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• 4C Medical Technologies
• Abbott Laboratories
• Affluent Medical
• Anteris Technologies
• Artivion, Inc.
• Bayer AG
• Boston Scientific Corporation
• Cadrenal Therapeutics, Inc.
• Colibri Heart Valve LLC
• Corcym UK Limited
• CryoLife, Inc.
• Edwards Lifesciences Corporation
• HighLife Medical
• Labcor Laboratorios Ltda
• Lepu Medical Technology Co., Ltd.
• LivaNova PLC
• Medtronic plc
• Micro Interventional Devices, Inc.
• Novartis AG
• Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Mitral Valve Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Mitral Regurgitation and Valve Prolapse Drives Demand for Advanced Therapeutics
  • Expansion of Structural Heart Disease Programs Throws the Spotlight on Percutaneous Mitral Valve Repair Solutions
  • Advancements in Transcatheter Mitral Valve Replacement (TMVR) Propel Minimally Invasive Treatment Options
  • Growth in Aging Population and Heart Failure Cases Strengthens Business Case for Early Intervention Therapies
  • Surge in Use of Echocardiography and Cardiac MRI Enhances Early Diagnosis and Monitoring of Mitral Disease
  • Regulatory Approvals of Novel Devices Like MitraClip Drive Adoption of Non-Surgical Repair Techniques
  • Increased Investment in Valve Repair Bioprosthetics and Annuloplasty Rings Fuels Innovation in Surgical Therapies
  • Expansion of Clinical Trial Pipelines for TMVR Systems Supports Portfolio Diversification Among MedTech Companies
  • Use of Robotic-Assisted and Image-Guided Surgery Enhances Procedural Precision and Patient Outcomes
  • Growth in Hybrid Operating Rooms and Interventional Cardiology Units Supports Multi-Modality Access
  • Emphasis on Valve-in-Valve and Valve-in-Ring Technologies Strengthens Retreatment Opportunities
  • Collaborations Between Device OEMs and Academic Hospitals Accelerate Trial Enrollment and Product Refinement
  • Increasing Focus on Post-Repair Heart Function and Quality of Life Metrics Drives Demand for Durable Therapies
  • Adoption of Risk Stratification Models Enhances Patient Selection for Surgical Versus Transcatheter Approaches
  • OEM-Driven Physician Training Programs Fuel Procedural Competence and Market Penetration
  • Global Expansion of Valve Repair Expertise in Emerging Cardiology Centers Spurs Regional Growth
  • Reimbursement Frameworks and Value-Based Care Models Drive Uptake of Cost-Efficient Valve Interventions
  • Growth in Mitral Valve Repair in Low-Risk and Intermediate-Risk Patients Expands Total Treatable Population
  • Emergence of Personalized Valve Therapies Using 3D Imaging and Computational Modeling Enhances Clinical Precision
  • Device Miniaturization and Delivery System Improvements Reduce Access Challenges in High-Risk Patients
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mitral Valve Disease Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Below 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Below 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Below 55 Years by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Above 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Above 55 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Above 55 Years by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• JAPAN
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• CHINA
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• EUROPE
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• FRANCE
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• GERMANY
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• INDIA
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Mitral Valve Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030
• AFRICA
  • Mitral Valve Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Mitral Valve Disease Therapeutics by Drug Class - Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Mitral Valve Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Beta Blockers, Diuretics, Anticoagulants and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Mitral Valve Disease Therapeutics by Age Group - Below 55 Years and Above 55 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Mitral Valve Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 55 Years and Above 55 Years for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Mitral Valve Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Mitral Valve Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION